TON - September 2018, Vol 11, No 4

• Venclexta Indicated for CLL or SLL, Alone or in Combination with Rituxan
• Keytruda Receives 2 New Indications: Metastatic Cervical Cancer and Relapsed Mediastinal Large B-Cell Lymphoma
• Bevacizumab Plus Chemotherapy Approved for Several Types of Ovarian Cancer

Read More ›

The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH. Read More ›

“Our study shows that medical marijuana is a salient topic in cancer care today, and the majority of oncologists think it may have utility for certain patients….however, data on medical marijuana use is less so,” said Ilana M. Braun, MD. Read More ›

Chicago, IL—In the United States, black men are twice as likely to die from prostate cancer as white men, and they are often diagnosed at a younger age and at later stages of the disease. Read More ›